Maze Therapeutics (MAZE) closed at $31.48 on October 30, 2026, down 1.4% from the previous close, on volume of 299,858 shares (30-day average 893,720).
Data as of October 30, 2026.
30-Oct-2026
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Globe Newswire (Tue, 6-Oct 4:05 PM ET)
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
Globe Newswire (Wed, 2-Sep 7:00 AM ET)
Maze Therapeutics Announces Appointments to Its Board of Directors
Globe Newswire (Thu, 13-Aug 4:42 PM ET)
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Globe Newswire (Tue, 11-Aug 4:01 PM ET)
Maze Therapeutics’ $150 Million Offering Set to Fund Research Pipeline Through 2029
Market Chameleon (Wed, 22-Apr 6:34 AM ET)
Market Chameleon (Thu, 26-Mar 7:45 AM ET)
Maze Therapeutics Advances Kidney Disease Pipeline with Strong Phase 2 Data and Expands Leadership
Market Chameleon (Wed, 25-Mar 3:54 AM ET)
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Maze Therapeutics trades on the NASDAQ stock market under the symbol MAZE.
As of October 30, 2026, MAZE stock price declined to $31.48 with 299,858 million shares trading.
MAZE has a beta of 1.28, meaning it tends to be more sensitive to market movements. MAZE has a correlation of 0.05 to the broad based SPY ETF.
MAZE has a market cap of $1.75 billion. This is considered a Small Cap stock.
Last quarter Maze Therapeutics reported $0 in Revenue and -$.76 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.05.
The top ETF exchange traded funds that MAZE belongs to (by Net Assets): VTI, IWM, VXF, XPH, IWO.
MAZE has underperformed the market in the last year with a return of -5.2%, while SPY returned +12.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MAZE shares. However, MAZE has outperformed the market in the last 3 month and 2 week periods, returning +13.9% and +14.3%, while SPY returned +2.1% and -1.0%, respectively. This indicates MAZE has been having a stronger performance recently.
MAZE support price is $30.75 and resistance is $33.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MAZE shares will trade within this expected range on the day.
